Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 Trials.
Daniel Garbin Di LucaEric A MacklinKaren HodgemanGisel LopezLindsay PothierKatherine F CallahanJill LowellJames ChanAleksandar VidenovicCodrin LunguAnthony E LangIrene LitvanMichael A SchwarzschildTatyana SimuniPublished in: Neurology. Clinical practice (2023)
This study used data from The Safety, Tolerability, and Efficacy Assessment of Isradipine for Parkinson Disease (STEADY-PD III; NCT02168842) and the Study of Urate Elevation in Parkinson's Disease (SURE-PD3; NCT02642393).